CHN1 is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Diffuse Large B-cell Lymphoma (DLBCL) is the most common B-cell malignancy with a significant rate of relapse or refractory disease despite standard treatment.
• Current gene-based prognostic methods for DLBCL have limitations, leaving some patients unclassified.
• There is a need for novel biomarkers to accurately predict DLBCL patient prognosis.

Purpose of the Study:

• To identify a novel prognostic biomarker for Diffuse Large B-cell Lymphoma (DLBCL).
• To investigate the prognostic significance of candidate genes in DLBCL patient outcomes.

Main Methods:

• Analysis of 1850 B-cell non-Hodgkin lymphoma (B-NHL) patient datasets with gene expression profiles from GEO and LLMPP.
• Selection of candidate genes through a strict filtering pipeline.
• Survival analysis, Gene Set Enrichment Analysis (GSEA), and CIBERSORT algorithm application to explore gene functions and prognostic value.

Main Results:

• Six candidate genes associated with DLBCL clinical outcome were identified, including CHN1, CD3D, CLU, ICOS, KLRB1, and LAT.
• CHN1, previously unreported in lymphoma, showed prognostic significance, particularly high expression correlating with better outcomes in specific DLBCL subgroups (GCB subtype, stage III-IV, IPI > 2).
• Multivariate Cox regression confirmed CHN1 as an independent prognostic factor, and GSEA/CIBERSORT linked it to cell adhesion and T cell immune infiltration.

Conclusions:

• High CHN1 expression is associated with favorable outcomes in DLBCL patients.
• CHN1 demonstrates potential as a novel prognostic marker for DLBCL.
• Further research into CHN1's role in DLBCL pathogenesis and immune infiltration is warranted.